|
業務類別
|
Biotechnology |
|
業務概覽
|
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy. |
| 公司地址
| 8 Davis Drive, Suite 220, Durham, NC, USA, 27709 |
| 電話號碼
| +1 984 884-6030 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.opusgtx.com |
| 員工數量
| 18 |
| Mr. Joseph K. Schachle |
Chief Operating Officer |
-- |
02/04/2025 |
| Dr. Benjamin R. Yerxa,PhD |
Director and President |
-- |
02/04/2025 |
| Dr. George Magrath, PhD |
Director and Chief Executive Officer |
-- |
02/04/2025 |
| Mr. Robert Gagnon, M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
02/09/2025 |
| Ms. Amy Rabourn |
Senior Vice President, Finance, Principal Financial Officer and Principal Accounting Officer |
-- |
25/06/2025 |
| Mr. Bernhard Hoffmann |
Senior Vice President, Corporate Development |
-- |
02/04/2025 |
| Dr. Ashwath Jayagopal, PhD |
Chief Scientific and Development Officer |
-- |
02/04/2025 |
|
|
| Dr. Benjamin R. Yerxa,PhD |
Director and President |
02/04/2025 |
| Dr. George Magrath, PhD |
Director and Chief Executive Officer |
02/04/2025 |
| Dr. Adrienne L. Graves,PhD |
Independent Director |
02/04/2025 |
| Dr. Jean Bennett, M.D.,Pd.D |
Director |
02/04/2025 |
| Dr. James S.J. Manuso, M.B.A.,PhD |
Independent Director |
02/04/2025 |
| Mr. Cam S. Gallagher |
Chairman of the Board |
02/04/2025 |
| Mr. Sean Ainsworth |
Lead Independent Director |
02/04/2025 |
| Ms. Susan K. Benton |
Independent Director |
02/04/2025 |
| Mr. Richard J. Rodgers |
Independent Director |
02/04/2025 |
|
|
|
|
